台灣臨床試驗主持人資料庫|TPIDB

問卷

問卷調查提醒

您好：邀請您填寫網站的問卷意見調查表，讓我們有更多優化及改進的方向，一起提升使用者體驗。

系統通知

此案目前為暫存狀態

編修至YYYY/MM/DD

不開放編輯功能

確認送出

我同意

請先勾選「我同意」

當您勾選「我同意」時，表示您已閱讀、了解並同意接受本「會員同意書及隱私權政策」內容

Log In

繁中 EN

TPIDB

TPIDB Outstanding PI Advanced Search 聯絡我們

繁中 EN

TPIDB Outstanding PI

TPIDB > Search Result

Search Result

請選擇要匯出的欄位

全選

Plan Title (TW)

Plan Title (EN)

Plan No

NCT No

Start Date

End Date

Trial Phase

ICD-9

ICD-10

Applicant

CRO (TW)

CRO (EN)

Trial Scale

Indication (TW)

Indication (EN)

Purpose (TW)

Purpose (EN)

Drug Name (TW)

Drug Name (EN)

ATC Code

Ingredient (TW)

Ingredient (EN)

Dose Type (TW)

Dose Type (EN)

Dose (TW)

Dose (EN)

Evaluation (TW)

Evaluation (EN)

Inclusions (TW)

Inclusions (EN)

Exclusions (TW)

Exclusions (EN)

Taiwan Quantity

Global Quantity

IIT

Hospital

PI

Accept Qty

Contact Name (TW)

Contact Name (EN)

Contact Phone (TW)

Contact Phone (EN)

Contact Email (TW)

Contact Email (EN)

Co-PI

Modify Search

Find Division/Department

Find Hospital

All Location

All Division/Department

All Division/Department
Division of Internal Medicine
Division of Surgery
Division of Others

篩選

Developmental Phase

Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others

Trial Status

Not yet recruiting
Active
Completed

Recruitment Status

Not yet recruiting
Recruiting
Completed
Terminated
Stop recruiting
Suspended
Study ended

Trial scale

Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization

Important Roles

Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None

Audit by Sponsors/CRO

Sponsors
CRO
None

Investigator-initiated trial(IIT)

Yes

Filters

李劭軒

Recruiting

List

124Cases

2025-04-01 - 2030-06-18

Phase III

Active

A phase III, randomized, open-label, commissioner-blinded, multicenter trial evaluating ribegostomig in combination with bevacizumab, with or without tremelimumab, as first-line treatment for patients with advanced hepatocellular carcinoma (ARTEMIDE-HCC01).

Condition/Disease

Advanced hepatocellular carcinoma
Test Drug

Atezolizumab Bevacizumab Rilvegostomig (AZD2936) Tremelimumab

Participate Sites
8Sites

Recruiting8Sites

2020-09-01 - 2026-12-31

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
4Sites

Recruiting4Sites

2018-05-01 - 2026-12-31

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-01-01 - 2026-12-31

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-05-01 - 2026-03-31

Phase II

Completed

Condition/Disease
Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-08-01 - 2026-12-31

Phase III

Active

Condition/Disease
Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2024-03-01 - 2028-06-30

Phase I/II

Active

Condition/Disease
Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-10-01 - 2030-12-31

Phase III

Active

Condition/Disease
Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-10-01 - 2027-12-31

Phase III

Active

Condition/Disease
Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2024-11-01 - 2031-06-30

Phase III

Active

Condition/Disease
Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 Previous page 4 5 6 7 8 Next page 13

搜尋計畫列表下載細項

全部

試驗主持人
實際收案人數

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB